Jean Michel Molina News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gonorrhea treatment: New antibiotic shows promise for drug-resistant infection

Gonorrhea treatment: New antibiotic shows promise for drug-resistant infection
nbcnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbcnews.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesSouth africaMargaret kozielJeffrey klausnerManica balasegaramJeanne marrazzoJean michel molinaGlobal antibiotic research development partnershipKeck school of medicineUniversity of parisNational institute of allergyCenters for diseaseDrug administrationMassachusetts department of public healthWorld health organization

New antibiotic shows promise for drug-resistant gonorrhea

New antibiotic shows promise for drug-resistant gonorrhea
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

France generalSouth africaUnited statesJean michel molinaManica balasegaramJeffrey klausnerMargaret kozielJeanne marrazzoCenters for diseaseGlobal antibiotic research development partnershipKeck school of medicineDrug administrationMassachusetts department of public healthWorld health organizationUniversity of parisNational institute of allergy

Gilead Sciences, Inc : Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

Gilead Sciences, Inc : Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

South africaUnited kingdomFrance generalUnited statesIhre chancenJean michel molinaIndiens wirtschaftMeaghan smithJacquie rossGilead sciencesGilead sciences incExchange commissionClinical developmentHead of the infectious diseases departmentGilead public affairsParis cit

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program - Gilead Sciences (NASDAQ:GILD)

– PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV pre-exposure prophylaxis (PrEP) in France and the United Kingdom – Gilead Sciences, Inc. (NASDAQ:GILD)

France generalUnited statesUnited kingdomSouth africaJean michel molinaHead of the infectious diseases departmentGilead sciences incGilead sciencesClinical developmentExchange commissionParis citInfectious diseasesInfectious diseases departmentJared baetenVice presidentImportant safety information

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program

FOSTER CITY, Calif., October 18, 2023 Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will assess the persistence—defined as consistent and continuous use—of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The study has an intention

United kingdomUnited statesFrance generalSouth africaJean michel molinaHead of the infectious diseases departmentExchange commissionGilead sciences incGilead sciencesGilead public affairsClinical developmentParis citInfectious diseasesInfectious diseases departmentJared baetenVice president